Enanta Pharmaceuticals
ENTA
ENTA
127 hedge funds and large institutions have $598M invested in Enanta Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
32% more capital invested
Capital invested by funds: $454M → $598M (+$144M)
4% more funds holding
Funds holding: 122 → 127 (+5)
0.83% more ownership
Funds ownership: 66.11% → 66.95% (+0.83%)
Holders
127
Holding in Top 10
3
Calls
$1.44M
Puts
$426K
Top Buyers
| 1 | +$29.1M | |
| 2 | +$19.3M | |
| 3 | +$9.36M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.79M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$4.49M |
Top Sellers
| 1 | -$17.5M | |
| 2 | -$7.3M | |
| 3 | -$7.2M | |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.79M |
| 5 |
KAM
Krensavage Asset Management
New York
|
-$4.27M |